Johnson & Johnson (JNJ) announced that the FDA has granted Fast Track designation to its Posdinema, a monoclonal antibody ...

The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...

A study has found cardiovascular conditions such as high blood pressure and diabetes, which are known to contribute to brain blood vessel damage in younger populations, not to be associated with an ...

A study from the Keck School of Medicine of USC has tested a biomarker linked to vascular dementia across four separate ...